Forschung

Arbeitsgruppe Professor Dr. K. Baumann
Arbeitsgruppe Professor Dr. C. Kunick
Arbeitsgruppe Professor Dr. H. Wätzig
Arbeitsgruppe Professor Dr. I. Ott
Stellenausschreibungen
Professor
Dr. K. Görlitzer (a. D.)
Professor
Dr. W. Kliegel (a. D.)
Professor
Dr. D. Moderhack (a. D.)
Professor em.
Dr. Dr. h.c. G. Zinner

  Arbeitsgruppe Professor Dr. Ingo Ott

Mitarbeiter: Andreas Meyer, Riccardo Rubbiani

 

 

 

 

 

 

Research

 

Jobs

 

 

 

 

 

 

 

Group

 

Publications

 

 


Research

Development of New Cytostatics

Bioinorganic and Bioorganometallic Medicinal Chemistry

Mission

The general aim of our research is the development of novel innovative anticancer drugs. Within this overall interest our current projects focus mainly on the design and preparation as well as the analytical and biological evaluation of new coordination complexes.

Based on their unique geometries and reactivities metal complexes offer interactions with biological targets that can not be realised with conventional "organic" drugs. Despite this advantage "metallodrugs" are rare in practical therapy and their impact in drug development has probably been underestimated so far. However, the continuing success story of the platinum antitumor drugs (e.g. cisplatin and carboplatin) as well as the promising preclinical results of various other coordination compounds demonstrate that metal species can be valuable therapeutics.

 

inhibition of proliferation

apoptosis induction

TrxR inhibition

inhibition of angiogenesis

inhibition of TrxR

monitoring of the fluorescent complex in MCF-7 cells

 

Over the last years gold complexes have attracted major attention as novel class of anticancer metallodrugs based on the discovery of significant antiproliferative effects triggered by antirheumatic gold species such as auranofin.

The gold phosphine complex Au-Naphth depicted in the figure above represents an example for a novel antiproliferative compound developed by our group recently. Au-Naphth exhibits several features, which are highly relevant for the development of novel antitumor therapeutics. The complex effectively inhibits the proliferation of cultured tumor cells and induces apoptosis via mitochondrial pathways. These properties can be related to an interaction with the DNA and an inhibition of the enzyme thioredoxin reductase. Biodistribution studies showed that the complex is taken up into different organelles and that the naphthalimide ligand leads to an accumulation of gold in the nuclei. Furthermore, Au-Naphth significantly reduced in-vivo angiogenesis in the zebrafish model.

 

Methods

Besides synthetic chemistry and structural characterisation of new antitumor drugs we strongly focus on an intensive biological evaluation of the new compounds. Relevant experimental procedures include the analysis of proliferation and apoptosis, bioanalytical studies (e.g. quantification of the cellular uptake) and various enzymatic assays.

 

Fundings

Our projects are currently supported by DFG (Deutsche Forschungsgemeinschaft), GIF (German-Israeli-Foundation) and Volkswagenstiftung.

  

 back to top


 The Group

 

 

 

 

J.-Prof. Dr. Ingo Ott

short CV

 

 Email

phone: +49 (0)531 391 2743

fax: +49 (0)531 391 8456

 

 

 

 

 

 

 

 

 

 

Andreas Meyer, Pharmacist

PhD student

 

 

 

 

 

 

 

 

 

 

Riccardo Rubbiani, Pharmacist

PhD student

 

 

 

 

 

 

 

 

 

 

 

 

 

 

back to top


Jobs

 At the moment all positions are filled.

 New openings will be announced on this website as soon as available.

 

 

 

 back to top


 

Publications

 

Journals

 

Reviews and other contributions in journals

 

 Patents

 

back to top